# Karyopharm Therapeutics Inc. (KPTI) — strategic_review/formal_alternatives [announced]
Source: SEC API (secapi.ai) · situation sit_e3aa1e8504a147b8104b · retrieved 2026-08-11T16:15:22.797Z

## Overview
Karyopharm Therapeutics Inc. develops selinexor and other drug candidates for the treatment of multiple myeloma, endometrial cancer, myelofibrosis, and other diseases.

Karyopharm Therapeutics Inc., a pharmaceutical company developing selinexor and other drug candidates, announced on July 30, 2026 that it is exploring potential financing transactions and strategic alternatives with the assistance of financial advisor Centerview Partners to extend its cash runway and maximize value for stakeholders. The company stated there is no assurance that these efforts will result in any transaction or what the ultimate terms would be, and does not intend to disclose further developments unless its Board approves a specific transaction or determines further disclosure is appropriate.

## Terms
- Counterparty: Centerview Partners

## Key dates
- Announced 2026-07-31

## Timeline
- 2026-07-31 · 8-K (0001193125-26-326995): 8-K - Karyopharm Therapeutics Inc. — *Karyopharm Therapeutics Inc. develops selinexor and other drug candidates for the treatment of multiple myeloma, endometrial cancer, myelofibrosis, and other diseases.* Karyopharm Therapeutics Inc., a pharmaceutical company developing selinexor and other drug candidates, announced on July 30, 2026 that it is exploring potential financing transactions and strategic alternatives with the assistance of financial advisor Centerview Partners to extend its cash runway and maximize value for stakeholders. The company stated there is no assurance that these efforts will result in any transaction or what the ultimate terms would be, and does not intend to disclose further developments unless its Board approves a specific transaction or determines further disclosure is appropriate.
  https://www.sec.gov/Archives/edgar/data/1503802/0001193125-26-326995.txt

## Citations
- 0001193125-26-326995 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526326995